Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
POLYCILLIN-PRB is an oral suspension combining ampicillin (a penicillin-class beta-lactam antibiotic) with probenecid (a uricosuric agent that inhibits renal tubular secretion). The probenecid component increases ampicillin serum levels by blocking renal excretion, enhancing antibiotic efficacy against susceptible bacterial infections. This combination targets bacterial infections where elevated ampicillin concentrations are therapeutically beneficial.
Pre-launch status indicates early-stage commercial infrastructure buildout; team expansion likely focused on launch readiness, market access, and regulatory compliance roles.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Joining POLYCILLIN-PRB's team offers early-stage career exposure to pre-launch brand building, regulatory strategy, and market positioning in a competitive generic-dominated space. Success requires strong fundamentals in access strategy, managed care negotiation, and field execution rather than clinical or pipeline innovation.
Worked on POLYCILLIN-PRB at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.